Latest News

Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases



Jeffrey Bluestone, the prominent immunologist, has decided to leave his position as president of the Parker Institute for Cancer Immunotherapy, the research effort funded by billionaire Sean Parker, and strike out on his own as CEO of a new company, Sonoma Biotherapeutics.

The departure, which occurred in December, means Bluestone is resigning from an organization that is trying to develop a new model for advancing cancer research and heading to a biotech startup that’s trying to do it in a more familiar way. Sonoma is trying to develop therapies that harness the immune system by treating not cancer but diseases of the immune system like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Read the rest…

Source link

Related posts

Medical News Today: Differences between ketosis and ketoacidosis

Newsemia

More than a third of youth with PTSD did not receive treatment in 2012

Newsemia

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World